ECOR:NASDAQ, electroCore, Inc.

Why ECOR stock fell on November 12

electroCore, Inc. fell 31.4% on Thursday, November 12, 2026, on 619,600 shares, 6.1 times its average daily volume. The headline around the move:

Nov 12: Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation

ECOR stock overview

electroCore, Inc. (ECOR:NASDAQ) closed at $5.25 on November 13, 2026, down 0.76% on the day. The stock trades 58.7% below its 52-week high of $12.70 and 20.1% above its 52-week low of $4.37. Over the past year, it lost 6.3%. electroCore, Inc. is part of the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus).

Key figures

Price: $5.25
Day change: -0.76%
Volume: 290,843
Average volume: 101,725
Market cap: 48M+
52-week range: $4.37 – $12.70
50-day average: $9.08
200-day average: $7.74

Price action over the past year

In 252 trading sessions since November 13, 2025, ECOR closed higher on 122 days (48%). Its best day was May 26, 2026 (+33.58%) and its worst was November 12, 2026 (-31.39%). The stock moved 10% or more in a single session 16 times.

Recent signals

Nov 13, 2026: Hit a new 6-Month Low of $5.25 (New Highs/Lows scanner)
Nov 6, 2026: Dropped 17.6% in a single session (Dips & Crashes scanner)
Nov 5, 2026: News catalyst: Guidance (News Catalysts scanner)

ECOR news

Nov 12, 2026: Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
Nov 9, 2026: electroCore (ECOR) Upgraded to Buy: Here's What You Should Know
Nov 5, 2026: electroCore (ECOR) Q3 2026 Earnings Call Transcript
Nov 5, 2026: electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Nov 5, 2026: electroCore Inc (ECOR) (Q3 2026) Earnings Call Highlights: Record Sales, Narrowing Losses, and ...
Nov 5, 2026: electroCore Q3 Earnings Call Highlights
Nov 5, 2026: ElectroCore Halves Its Loss And Beats On EPS, But A Revenue Miss, Slowing Growth And A Guidance Cut Push The Story Into 2027
Nov 4, 2026: electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue Estimates

About electroCore, Inc.

Electrocore LLC is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology.

Similar stocks

Find more stocks like ECOR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.